The goal of this clinical trial is to learn if a Nepalese Pepper Extract (Zanthoxlum Armatum, ZA) supplement can improve cognitive performance and mental abilities in competitive gamers aged 16 to 34. The main questions it aims to answer are:
1. Does ZA supplement improve cognitive abilities like attention, memory, and decision-making? 2. What is the most effective dose of ZA supplement (300mg vs 150mg)? 3. How do the effects of ZA supplement compare to caffeine?
Researchers will compare four different treatments (high-dose ZA, low-dose ZA, caffeine, and placebo) to see if ZA supplement produces better cognitive performance than placebo and how it compares to caffeine\*\*.
Participants will:
* Complete a screening visit with health checks and training on computer tasks * Attend four testing visits (7-14 days apart) where they receive different treatments * Avoid alcohol and energy drinks for 24 hours before each visit, and caffeine from waking * Take assigned treatment at 11:30am and complete cognitive tests at -1, 1, 3, and 5 hours in relation to dose. * Complete mood questionnaires, sleep assessments, and gaming-specific tasks (aim training, character control) * Wear heart rate monitors during testing * Eat standardized meals provided during visits * Play competitive games at home in the evening and complete performance questionnaires
Aged 16 to 34 years inclusive
Males and females
Self-report of good health
Usually a regular (at least once per week) player of competitive multiplayer games, (prospective participants will be asked to contact the researchers to discuss their gaming habits if uncertain that they meet the criteria).
Have any pre-existing medical condition/illness which will impact taking part in the study (i.e. participants may be allowed to progress to screening if they have a condition/illness which would not interact with the active treatments or impede performance).
Are currently taking prescription medications NOTE: the explicit exceptions to this are contraceptive treatments for female participants, and those taken 'as needed' in the treatment of asthma and hay fever. There may be other instances of medication use which, where no interaction with the active treatments is likely, and which would not be expected to have any impact on brain function, participants may be able to progress to screening.
Have high blood pressure (systolic over 139 mm Hg or diastolic over 89 mm Hg); or have low blood pressure (systolic below 90 mm Hg or diastolic below 60 mm Hg)
Have a Body Mass Index (BMI) outside of the range 18.5-35 kg/m2
Northumbria University
Lead sponsor
Mibelle Group Biochemistry
Collaborator